Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
Want to see BLTE full AI Analyst Report?
BLTE Stock Chart & Stats
$165.45
-$1.45(-2.47%)
At close: 4:00 PM EST
$165.45
-$1.45(-2.47%)
Day’s Range― - ―
52-Week Range$56.10 - $200.00
Previous CloseN/A
Volume15.47K
Average Volume (3M)64.23K
Market Cap
$5.54B
Enterprise Value$5.43B
Total Cash (Recent Filing)$492.42M
Total Debt (Recent Filing)$429.00K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 12, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding39,965,313
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-88.68
Forecast
1Y Price Target
$216.20Price Target Upside30.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.19
Revenue Forecast (FY)$22.50M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA very strong balance sheet with minimal debt and a large equity base provides durable financial flexibility to fund late‑stage development, the NDA process, and initial commercialization without immediate reliance on dilutive financing, supporting multi‑quarter execution risk.
Regulatory Progress (NDA Rolling)Initiating a rolling NDA after receiving the Phase 3 report materially shifts the company toward a commercial inflection point. This structural progress reduces long‑term program risk versus earlier stages and, if successful, converts R&D investment into recurring product revenues.
Commercial Buildout & Manufacturing ReadinessAdvance hiring of commercial leadership and operational scale‑up, combined with a straightforward small‑molecule manufacturing profile, meaningfully lowers execution risk for launch readiness and payer engagement, enabling faster market access if regulatory approval is achieved.
Bears Say
Widening Cash BurnSustained and accelerating negative operating cash flow is a durable structural headwind: it increases dependency on existing cash reserves or future financing, reduces optionality for strategic moves, and heightens exposure to funding risk if development timelines or costs inflate.
Rising Losses And Expense BaseRapidly expanding R&D and SG&A driving much larger GAAP losses creates a larger bridge to profitability. Until approval and product revenue materialize, elevated spend increases runway sensitivity to delays and can pressure returns on the significant capital base.
Regulatory & Clinical Timing RiskOngoing regulatory uncertainty—possible requirements to complete additional follow‑up and unknown GA interim outcomes—can materially delay approval, raise trial costs, and compress the window for peak revenue, making commercial timelines and investment payback more uncertain.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $56.10 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $5.54B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Aug 12, 2026 which is in 56 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on May 20, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.635 by $0.295.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.77.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 39,965,313 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.635. Following the earnings report the stock price went up 2.62%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$216.20 (30.67% Upside)
$216.20 (30.67% Upside)
Hedge Fund Trend
Decreased
By 584.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
-26.70%
Trailing 12-Months
Asset Growth
394.07%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program and commercial progress—Phase 3 report received, NDA rolling submission underway, Dragon 2 enrollment completed, substantial commercial hires, and a robust cash position (~$799M). However, the company is incurring sharply higher R&D and SG&A expenses, net losses widened materially, and several clinical and regulatory uncertainties remain (GA interim unknown; FDA guidance requires completion of Dragon 1 at 2 years). On balance the positive development and financial runway outweigh the near‑term expense and uncertainty headwinds.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$216.20
▲(30.67% Upside)
Technical Analysis
Denali Therapeutics
―
Kiniksa Pharmaceuticals
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
Ownership Overview
0.99% Insiders
0.78% Mutual Funds
17.21% Other Institutional Investors
80.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---